Literature DB >> 7302117

Minoxidil in the management of intractable hypertension.

A Mackay, C Isles, I Henderson, R Fife, A C Kennedy.   

Abstract

Eighty-seven patients with intractable hypertension received minoxidil for a mean duration of 27 months (range three months to five years). A significant reduction in mean outpatient blood pressure from 206/129 to 158/98 mmHg (p less than 0.001 for both systolic and diastolic values) was recorded after one month's treatment. In 26 patients who received minoxidil for four or more years a further reduction in mean blood pressure to 147/89 mmHg was achieved. The mean daily dose of minoxidil was 23 mg (range 2.5 to 60 mg). In all patients a beta adrenergic neurone blocker and a diuretic were prescribed with minoxidil to counteract tachycardia and fluid retention. Thirteen patients required the addition of a fourth hypotensive agent. The use of minoxidil led to simpler drug regimens with the majority of patients well controlled on twice daily or once daily schedules. Most patients commented spontaneously on a feeling of improved wellbeing while taking minoxidil which also appeared to be relatively free from side effects commonly encountered with other hypotensive drugs, particularly drowsiness, dizziness and impotence. Fluid retention of 7 kg or more occurred in 18 patients, more commonly in those with renal impairment, but could be controlled by increasing the dose or potency of diuretics. Four patients with end stage renal failure and one patient with normal renal function developed pericardial effusions. Hirsutism was universal and limited the usefulness of the drug in women. We currently recommend minoxidil for hypertensive men who diastolic blood pressure remains greater than or equal to 110 mmHg despite an adequate trial of a beta adrenergic neurone blocker, diuretic and an additional drug, or for patients who find the side effects of such therapy intolerable.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7302117

Source DB:  PubMed          Journal:  Q J Med        ISSN: 0033-5622


  11 in total

1.  Felodipine as an alternative to minoxidil in severe refractory hypertension.

Authors:  C G Wathen; D MacLeod; L Tucker; A L Muir
Journal:  Drugs       Date:  1985       Impact factor: 9.546

Review 2.  Hirsutism: evaluation and management.

Authors:  R E Watson; R Bouknight; P C Alguire
Journal:  J Gen Intern Med       Date:  1995-05       Impact factor: 5.128

3.  Vasodilators: minoxidil and drugs used in peripheral vascular and cerebral disorders.

Authors:  G D Lowe
Journal:  Br Med J (Clin Res Ed)       Date:  1983-04-16

4.  Management of intractable hypertension.

Authors:  A Mackay
Journal:  J R Soc Med       Date:  1983-07       Impact factor: 5.344

5.  Prospective measurement of glomerular filtration rate and effective renal plasma flow during treatment of malignant essential hypertension.

Authors:  R R Ghose
Journal:  Postgrad Med J       Date:  1984-10       Impact factor: 2.401

6.  Treatment of essential hypertension and hypertension associated with renal impairment with pinacidil: a new vasodilator.

Authors:  E G Breen; D Mulhall; J A Keogh
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

7.  "Third drug" trial: comparative study of antihypertensive agents added to treatment when blood pressure remains uncontrolled by a beta blocker plus thiazide diuretic.

Authors:  D McAreavey; L E Ramsey; L Latham; A D McLaren; A R Lorimer; J L Reid; J I Robertson; M P Robertson; R J Weir
Journal:  Br Med J (Clin Res Ed)       Date:  1984-01-14

8.  Long-term effects of pinacidil in hypertensive dialysis patients.

Authors:  E G Breen; D Mulhall; J A Keogh
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 9.  Direct vasodilators and their role in hypertension management: minoxidil.

Authors:  D A Sica; T W Gehr
Journal:  J Clin Hypertens (Greenwich)       Date:  2001 Mar-Apr       Impact factor: 3.738

Review 10.  Minoxidil: an underused vasodilator for resistant or severe hypertension.

Authors:  Domenic A Sica
Journal:  J Clin Hypertens (Greenwich)       Date:  2004-05       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.